Stoppers and non-starters of disease-modifying treatment in multiple sclerosis.

Grytten, N; Aarseth, J H; Espeset, K; Johnsen, G B; Wehus, R; Lund, C; Haugstad, R C

Grytten, N; Aarseth, J H; Espeset, K; Johnsen, G B; Wehus, R; Lund, C; Haugstad, R C.

Affiliation

Grytten N; National Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway. nina.grytten.torkildsen@helse-bergen.no

Acta Neurol Scand ; 127(2): 133-40, 2013 Feb.

Article in En | MEDLINE | ID: mdl-22924678

Subject(s)

Immunosuppressive Agents/therapeutic use; Medication Adherence/statistics & numerical data; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Adult; Cohort Studies; Female; Glatiramer Acetate; Humans; Interferon-beta/therapeutic use; Male; Medication Adherence/psychology; Multiple Sclerosis, Relapsing-Remitting/psychology; Norway; Peptides/therapeutic use; Retrospective Studies; Risk Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Medication Adherence / Immunosuppressive Agents Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Acta Neurol Scand Year: 2013 Document type: Article Affiliation country: Norway Country of publication: Denmark

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google